Trial · NCT02497287
Adverse events216
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 216
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | IND: Intranasal Esketamine + Oral AD | 68 | 779 | |
| other | Vertigo | Ear and labyrinth disorders | OP/MA: Intranasal Esketamine + Oral AD | 43 | 603 | |
| other | Vertigo | Ear and labyrinth disorders | FU: Intranasal Esketamine + Oral AD | 1 | 357 | |
| other | Vision Blurred | Eye disorders | IND: Intranasal Esketamine + Oral AD | 49 | 779 | |
| other | Vision Blurred | Eye disorders | OP/MA: Intranasal Esketamine + Oral AD | 25 | 603 | |
| other | Vision Blurred | Eye disorders | FU: Intranasal Esketamine + Oral AD | 0 | 357 | |
| other | Diarrhoea | Gastrointestinal disorders | IND: Intranasal Esketamine + Oral AD | 27 | 779 | |
| other | Diarrhoea | Gastrointestinal disorders | OP/MA: Intranasal Esketamine + Oral AD | 39 | 603 | |
| other | Diarrhoea | Gastrointestinal disorders | FU: Intranasal Esketamine + Oral AD | 2 | 357 | |
| other | Hypoaesthesia Oral | Gastrointestinal disorders | IND: Intranasal Esketamine + Oral AD | 63 | 779 | |
| other | Hypoaesthesia Oral | Gastrointestinal disorders | OP/MA: Intranasal Esketamine + Oral AD | 28 | 603 | |
| other | Hypoaesthesia Oral | Gastrointestinal disorders | FU: Intranasal Esketamine + Oral AD | 0 | 357 | |
| other | Nausea | Gastrointestinal disorders | IND: Intranasal Esketamine + Oral AD | 157 | 779 | |
| other | Nausea | Gastrointestinal disorders | OP/MA: Intranasal Esketamine + Oral AD | 84 | 603 | |
| other | Nausea | Gastrointestinal disorders | FU: Intranasal Esketamine + Oral AD | 2 | 357 | |
| other | Vomiting | Gastrointestinal disorders | IND: Intranasal Esketamine + Oral AD | 56 | 779 | |
| other | Vomiting | Gastrointestinal disorders | OP/MA: Intranasal Esketamine + Oral AD | 45 | 603 | |
| other | Vomiting | Gastrointestinal disorders | FU: Intranasal Esketamine + Oral AD | 2 | 357 | |
| other | Fatigue | General disorders | IND: Intranasal Esketamine + Oral AD | 40 | 779 | |
| other | Fatigue | General disorders | OP/MA: Intranasal Esketamine + Oral AD | 28 | 603 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02497287/events